Cardiff Oncology Inc (CRDF)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $56.49M
Last updated: Nov 17, 2026 at 11:04 AM ET
Cardiff Oncology Inc (CRDF) Stock Forecast
Analysts expect Cardiff Oncology (CRDF) to earn -$0.56 per share in the fiscal year ending Dec 31, 2026, on revenue of $364500. Of 6 analysts, 3 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 16.7% |
| Buy | 2 | 33.3% |
| Hold | 3 | 50.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 5.6%.
- Fiscal year ending Dec 31, 2026
- -$0.56
- EPS consensus, revenue $364500
- Fiscal year ending Dec 31, 2027
- -$0.52
- EPS consensus, revenue $385000
- Next report
- Feb 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.56 | -$0.56 to -$0.55 | 3 | $364500 | $166000 to $445000 | 6 |
| Dec 31, 2027 | -$0.52 | -$0.76 to -$0.33 | 4 | $385000 | N/A | 5 |
Quarterly Estimates
The EPS consensus rises from -$0.16 for the quarter ending Dec 31, 2026 to -$0.13 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.16 | -$0.21 to -$0.09 | 9 | $84997 | N/A | 9 |
| Mar 31, 2027 | -$0.13 | -$0.16 to -$0.09 | 2 | $116670 | $50000 to $200000 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 0 |
| Fiscal year ending Dec 31, 2027 | 4 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.55.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.56 | -$0.56 | -$0.56 | -$0.56 | -$0.55 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.52 | -$0.54 | -$0.54 | -$0.60 | -$0.63 | N/A |
| Quarter ending Mar 31, 2027 | -$0.13 | -$0.13 | -$0.13 | -$0.15 | -$0.15 | N/A |
Frequently Asked Questions About CRDF
What is the CRDF stock forecast?
Consensus analyst estimates put Cardiff Oncology's EPS at -$0.56 for the fiscal year ending Dec 31, 2026, on revenue of $364500. The consensus rating from 6 analysts is Buy.
How do analysts rate CRDF stock?
Of 6 analysts covering Cardiff Oncology, 1 rates it Strong Buy, 2 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CRDF next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.56, with estimates from -$0.56 to -$0.55 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.52, with estimates from -$0.76 to -$0.33 from 4 analysts.
What revenue do analysts expect from Cardiff Oncology next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $364500, with estimates from $166000 to $445000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $385000.
How many analysts cover CRDF?
6 analysts rate Cardiff Oncology stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CRDF pages: Overview, Earnings, Forecast, Financials, Competitors